Physician profile
Christopher Chu
NPI 1912369273
$8,012.28
in general payments reported to CMS, 2019-2025
13 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $4.74 · 2023: $767 · 2024: $6,432 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,200 · Food and Beverage: $2,402 · Travel and Lodging: $155 · Education: $56.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,200.00 |
| Food and Beverage | $2,402.02 |
| Travel and Lodging | $154.92 |
| Education | $56.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $6,087.06 | 2024-2025 | Livmarli |
| Boston Scientific Corporation | $591.43 | 2023-2025 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Alcresta Therapeutics, INC. | $269.53 | 2024-2025 | Relizorb |
| Abbvie INC. | $194.45 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $166.06 | 2023 | Arcalyst |
| Conmed Corporation | $164.30 | 2023-2025 | Conmed Hemostasis, Conmed Biliary, Conmed Generators |
| Regeneron Healthcare Solutions, INC. | $156.65 | 2023-2025 | Dupixent, Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $145.87 | 2024 | Arcalyst |
| Genzyme Corporation | $73.19 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $69.78 | 2025 | Iqirvo |
| Bayer Healthcare Pharmaceuticals INC. | $56.15 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.07 | 2024 | Eohilia |
| Travere Therapeutics, INC. | $4.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.